Clinical efficacy of cinacalciclovir hydrochloride combined with low-dose calcitriol in the treatment of patients with secondary hyperparathyroidism of end stage renal disease

Objective To investigate the effect of cinacalcet combined with low-dose calcitriol in the treatment of patients with secondary hyperparathyroidism of end-stage renal disease. Methods A prospective analysis was conducted in 129 patients with end-stage renal disease and secondary hyperparathyroidism from April 2015 to August 2017 in the Department of Nephrology of Integrative Medicine Hospital of Wenzhou City, Zhejiang Province.The patients were randomly divided into 3 groups: group A received cinacalcet, group B received calcitriol, group C received cinacalcet and low-dose calcitriol for 3 months, respectively.Before and after treatment, the levels of serum phosphorus and serum calcium in the three groups were measured.The levels of parathyroid hormone and the parathyroid hormone clearance rate were measured to find out the therapeutic effect. Results The levels of serum calcium, phosphorus and total parathyroid hormone in group A were significantly lower than those before treatment(t=3.269, 2.263, 4.233, all P 0.05). The total parathyroid hormone level: group B> group A > group C, the whole parathyroid hormone clearance rate: group C > group A > group B, the differences were statistically significant(t=3.642, 3.263, all P group C> group A, the serum phosphorus level among the three groups after treatment had statistically significant difference, group B> group A > group C (t=3.265, 3.332, all P<0.05). Conclusion The combined use of cinacalcet and low-dose calcitriol in the treatment of secondary hyperparathyroidism in patients with end-stage renal disease can significantly reduce the level of parathyroid hormone and serum phosphorus, and without affecting serum calcium concentration. Key words: Hyperparathyroidism; Kidner disease; Calcitriol; Sillocaine; Phosphorus; Calcium